{"id": "chatcmpl-8JZlumJloHdrAwtidsMDF1wL87iBX", "object": "chat.completion", "created": 1699676430, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. The blood pressure lowering efficacy and safety of CKD-828 is being evaluated.\n2. CKD-828 is a fixed-dose combination of S-amlodipine and telmisartan.\n3. S-amlodipine is the more active isomer of amlodipine besylate.\n4. Amlodipine besylate is a calcium channel blocker.\n5. Telmisartan is a long acting angiotensin receptor blocker.\n6. The evaluation is being conducted on patients with hypertension.\n7. These patients' hypertension is inadequately controlled with S-amlodipine monotherapy."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 113, "completion_tokens": 133, "total_tokens": 246}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: To evaluate the blood pressure (BP) lowering efficacy and safety of CKD-828, a fixed-dose combination of S-amlodipine (the more active isomer of amlodipine besylate, which is calcium channel blocker) and telmisartan (long acting angiotensin receptor blocker), in patients with hypertension inadequately controlled with S-amlodipine monotherapy.\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}